Journal
CARDIOVASCULAR THERAPEUTICS
Volume 35, Issue 2, Pages -Publisher
WILEY-HINDAWI
DOI: 10.1111/1755-5922.12241
Keywords
ADMA; Chronic heart failure; DDAH; Isoproterenol; NO; Rosuvastatin
Funding
- Ningxia Natural Science Foundation of P. R. China [NZ 16270]
Ask authors/readers for more resources
AimsCardiovascular disease is the leading cause of death with high morbidity and mortality, and chronic heart failure is the terminal phase of it. This study aimed to investigate the protective effects of the low-dose rosuvastatin on isoproterenol-induced chronic heart failure and to explore the possible related mechanisms. MethodsMale Sprague Dawley rats were given isoproterenol 5mg/kg once a day for 7days to establish heart failure model by subcutaneous injection. Simultaneously, low-dose rosuvastatin (5mg/kg) was orally administrated from day 1 to day 14. Protective effects were evaluated by hemodynamic parameter, histopathological variables, serum asymmetric dimethylarginine (ADMA), cardiac troponin I (cTnI), brain natriuretic peptide (BNP) and myocardial nitric oxide (NO), and the levels of dimethylarginine dimethylaminohydrolase 2 (DDAH2), arginine methyltransferases 1 (PRMT1) and endothelial nitric oxide synthase (eNOS) expression were analyzed. ResultsTherapeutic rosuvastatin (5mg/kg) significantly attenuated isoproterenol-induced hypertrophy, remodeling and dysfunction of ventricle, reduced the increased serum content of ADMA, cTnI, and BNP, and elevated myocardial NO in rats (P<.05). Besides, rosuvastatin also significantly inhibited fibrosis of myocardium, normalized the increased PRMT1 and decreased DDAH2 expression. ConclusionsLow-dose rosuvastatin exerted cardioprotective effects on isoproterenol-induced heart failure in rats by modulating DDAH-ADMA-NO pathway, and it may present the new therapeutic value in ameliorating chronic heart failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available